What Coherus Biosciences does

Coherus Biosciences (now operating as Coherus Oncology) is a Redwood City, California-based commercial-stage biopharmaceutical company that develops, manufactures, and commercializes biologic therapeutics for oncology and inflammatory diseases. Founded in 2010 by Denny Lanfear and listed on NASDAQ under ticker CHRS, the company employs 101-250 people and operates a corporate headquarters at 333 Twin Dolphin Drive in Redwood City with a laboratory and manufacturing facility in Camarillo, California. Coherus underwent a strategic transformation in the 2023-2025 period, divesting its legacy pegfilgrastim biosimilar franchise (UDENYCA, sold to Intas Pharmaceuticals for $558.4 million in August 2025) and pivoting to become a pure-play immuno-oncology innovator.

The company's core product is LOQTORZI (toripalimab-tpzi), a next-generation anti-PD-1 monoclonal antibody that received FDA approval on October 27, 2023 for the treatment of recurrent, locally advanced or metastatic nasopharyngeal carcinoma (NPC), making it the only FDA-approved therapy for this indication. Clinical data from the Phase 3 JUPITER-02 trial demonstrated a 38% reduction in risk of death and a 31-month improvement in median overall survival (64.8 vs 33.7 months) versus chemotherapy alone. The company is building a diversified immuno-oncology pipeline around the LOQTORZI backbone with two clinical-stage candidates: tagmokitug (anti-CCR8, designed to selectively deplete tumor-resident regulatory T cells) and casdozokitug (anti-IL-27, first-in-class antibody antagonist with FDA Orphan Drug designation for hepatocellular carcinoma). Pipeline indications span hepatocellular carcinoma, head and neck squamous cell carcinoma, gastric/GEJ/esophageal cancers, colorectal cancer, and metastatic castration-resistant prostate cancer.

Coherus generates revenue through direct US sales of LOQTORZI to oncologists, hospitals, and cancer treatment centers via an enterprise field sales force, supported by medical affairs and market access teams. International commercialization is pursued through licensing partnerships, with Apotex Inc. holding exclusive Canadian rights following Health Canada approval in October 2025. Revenue is supplemented by licensing and royalty streams from such partnerships. FY2025 LOQTORZI net revenue was $40.8 million (more than doubled from $19 million in 2024), with Q1 2026 revenue of $11.8 million representing 61% year-over-year growth. The company maintains clinical collaborations with Johnson & Johnson (tagmokitug combination in mCRPC), Zumutor Biologics (ZM008 combination), and Inovio Pharmaceuticals (DNA-based cancer immunotherapy combinations) to extend the platform without full infrastructure investment. As of Q1 2026, the company held $167.0 million in cash and cash equivalents with debt reduced to $3.7 million following the UDENYCA divestiture.

Name

Coherus Biosciences

Legal name

Coherus BioSciences, Inc.

Website

http://www.coherus.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

101–250 employees

Short description

Coherus Biosciences is a Redwood City-based biopharmaceutical company that develops and commercializes immuno-oncology therapeutics, led by FDA-approved LOQTORZI (toripalimab) for nasopharyngeal carcinoma and a clinical pipeline of anti-CCR8 and anti-IL-27 antibody candidates targeting solid tumors.

Ownership category

akta.pro rank

Product category

Immuno-Oncology Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industry

Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling) (HLAAAMAK)

Keywords

• Immuno-oncology therapeutics
• Monoclonal antibody drugs
• Oncology biologics
• PD-1 inhibitors
• Cancer immunotherapy

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain

Revenue model

1. LOQTORZI Product Sales: Revenue from sales of FDA-approved PD-1 inhibitor LOQTORZI (toripalimab-tpzi) for nasopharyngeal carcinoma treatment in the US market. Q1 2026 net revenue of $11.8 million representing 61% increase over Q1 2025. Full year 2025 net revenue of $40.8 million, more than doubled from $19 million in 2024.
2. Licensing and Royalty Revenue: Revenue from licensing Canadian commercialization rights for LOQTORZI to Apotex Inc., and potential future licensing deals for ex-US development and commercialization rights in emerging markets.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Coherus Biosciences (also known as Coherus Oncology) develops, manufactures, and commercializes biologic therapeutics for oncology. Its commercial product LOQTORZI (toripalimab-tpzi) is an FDA-approved next-generation anti-PD-1 monoclonal antibody for nasopharyngeal carcinoma. The company is also advancing a clinical pipeline of novel immuno-oncology antibodies including tagmokitug (anti-CCR8) and casdozokitug (anti-IL-27) that target the tumor microenvironment to overcome immune resistance in solid tumors.

Product overview

Coherus Oncology is a commercial-stage biopharmaceutical company focused on developing and commercializing a diversified portfolio of next-generation immuno-oncology therapies. The company's core product is LOQTORZI (toripalimab-tpzi), an FDA-approved PD-1 inhibitor for nasopharyngeal carcinoma. Coherus is building a pipeline of novel immuno-oncology candidates including Tagmokitug (anti-CCR8 antibody) and Casdozokitug (anti-IL-27 antibody), targeting the tumor microenvironment to overcome immune resistance in cancer. The company previously commercialized biosimilar products including UDENYCA, which was sold to Intas Pharmaceuticals in 2025.

Differentiator

Problem solved

Functional benefit

Brands

• LOQTORZI: FDA-approved PD-1 inhibitor (toripalimab-tpzi) for treatment of recurrent, locally advanced or metastatic nasopharyngeal carcinoma
• Coherus Solutions
• Toripalimab-tpzi

Products and services

• LOQTORZI (toripalimab-tpzi) LOQTORZI is a next-generation PD-1 monoclonal antibody that blocks PD-L1 and PD-L2 binding to the PD-1 receptor with high potency at a unique site, enabling the immune system to activate and kill tumors. It is the only FDA-approved therapy for recurrent, locally advanced or metastatic nasopharyngeal carcinoma, indicated for use in combination with chemotherapy or as monotherapy. It is sold to oncologists, hospitals, and cancer treatment centers in the United States.
• Tagmokitug (anti-CCR8) Tagmokitug is a highly selective anti-CCR8 cytolytic antibody (ADCC-enhanced) designed to selectively deplete tumor resident regulatory T cells (Tregs) that suppress anti-tumor immune response, while sparing T cells and CCR8-negative Tregs in normal tissue. It is being developed for solid tumor indications including metastatic castration-resistant prostate cancer.
• Casdozokitug (anti-IL-27) Casdozokitug is a first-in-class anti-IL-27 antibody antagonist designed to inhibit the immunosuppressive activity of IL-27 cytokine, enabling anti-tumor immune activation when combined with other cancer therapies including anti-PD-1 inhibitors. It has received FDA Orphan Drug designation for hepatocellular carcinoma.

Quantifiable outcome

• 38% reduction in risk of death (HR 0.62) and 31-month improvement in median OS (64.8 vs 33.7 months) with LOQTORZI plus chemotherapy vs chemotherapy alone in nasopharyngeal carcinoma
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Zumutor BiologicscoreStrategic or Co-development Partner · 23 June 2026Clinical collaboration to evaluate ZM008 in combination with LOQTORZI (toripalimab-tpzi). Both parties will retain their respective commercial rights. No additional details regarding financial terms disclosed.
• Johnson & JohnsoncoreStrategic or Co-development Partner · 4 February 2026Clinical supply agreement for a Phase 1b trial evaluating JNJ's pasritamig (T-cell engaging bispecific antibody) in combination with Coherus's tagmokitug in metastatic castration-resistant prostate cancer (mCRPC). Oppenheimer cited this as additional large pharma validation of the CCR8 target.
• Apotex Inc.coreChannel Partner/ Reseller/ Distributor · 23 October 2025Licensing agreement granting Apotex exclusive rights to commercialize and sell LOQTORZI in Canada. Apotex received Health Canada approval for LOQTORZI as the first and only Health Canada-approved immuno-therapy for recurrent unresectable or metastatic nasopharyngeal cancer. This marks Apotex's first novel biologic therapy.
• Intas PharmaceuticalsminorOthers · 1 August 2025Intas Pharmaceuticals acquired the Udenyca franchise from Coherus BioSciences for $558.4 million, strengthening both companies' positions in the pegfilgrastim biosimilar segment. The deal closed in August 2025.
• Inovio PharmaceuticalsminorStrategic or Co-development Partner · 1 January 2024Partnership to advance DNA-based cancer immunotherapies combining INO-3113 with LOQTORZI for HPV-associated cancers.
• Surface Oncology Inc.coreStrategic or Co-development Partner · 1 September 2023Coherus acquired Surface Oncology in a stock-for-stock transaction valued at up to $65 million, expected to close in Q3 2023. The acquisition expanded Coherus' immuno-oncology pipeline with SRF388 (now casdozokitug, anti-IL-27) and SRF114 (now tagmokitug, anti-CCR8), targeting the tumor microenvironment.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Merck & Co. Owner of Keytruda (pembrolizumab), the dominant PD-1 inhibitor and Coherus's primary competitor in the broader checkpoint inhibitor space. While not a direct competitor in NPC, Keytruda represents the benchmark that any LOQTORZI label expansion will be measured against. Both companies operate in immuno-oncology with monoclonal antibody platforms.
• Bristol-Myers Squibb: Owner of Opdivo (nivolumab), the second-leading PD-1 inhibitor globally. BMS has board representation connected to Coherus through former employees, and Opdivo competes with LOQTORZI in shared indications (head/neck cancer, gastric cancer). BMS represents the established PD-1 incumbent that Coherus must differentiate against.
• Regeneron Pharmaceuticals: Established antibody platform company with multiple FDA-approved biologics including Libtayo (cemiplimab, a PD-1 inhibitor). Regeneron is a broad incumbent in monoclonal antibody therapeutics with a deep pipeline in immuno-oncology, oncology bispecifics, and inflammation — directly relevant to Coherus's IO antibody platform approach.
• Gilead Sciences: Major biopharmaceutical company with oncology franchise including Trodelvy (ADC) and cell therapy via Kite. Gilead has a history of acquiring smaller oncology companies (Immunomedics, Forty Seven) and Coherus CFO Bryan McMichael previously worked at Gilead. While not a direct PD-1 competitor, Gilead is a relevant strategic acquirer and peer in the oncology therapeutics space.

Direct peers

• BeiGene: Commercializes tislelizumab, a Chinese-developed PD-1 antibody with global commercialization. BeiGene is the most direct competitive peer to Coherus — a smaller biopharmaceutical company that has leveraged a Chinese-originated PD-1 antibody to build a US/EU oncology franchise, mirroring Coherus's toripalimab strategy. Both companies target similar hematology/oncology indications with checkpoint inhibitors.
• Innovent Biologics: Chinese biopharmaceutical company that developed sintilimab (PD-1) and partners with Eli Lilly for international markets. Innovent is a direct strategic peer to Coherus in bringing a Chinese-originated PD-1 antibody to global markets, with overlapping oncology indications and similar partnership-driven commercial models.

Peers

• Shanghai Junshi Biosciences: Original developer of toripalimab (LOQTORZI's active ingredient) and Coherus's licensor for US/Canada rights. Junshi is the originator peer — both companies commercialize the same molecule in different geographies, with Coherus holding North American rights. Junshi also commercializes other immuno-oncology assets including anti-PD-L1 (adebrelimab) and anti-BTLA (tifcemalimab), making it a directly comparable Chinese immuno-oncology peer.

Emerging players

• MacroGenics: Clinical-stage biopharmaceutical company developing monoclonal antibodies and antibody-drug conjugates for cancer, including PD-1 inhibitors and Fc-engineered antibodies. MacroGenics is a comparable emerging immuno-oncology peer with similar size and pipeline-stage assets targeting solid tumors with antibody-based mechanisms.
• Werewolf Therapeutics: Clinical-stage immuno-oncology company developing INDUKINE therapeutics (tumor microenvironment-targeted immunotherapies). Werewolf focuses on overcoming immune resistance through innovative mechanisms — directly comparable to Coherus's CCR8/IL-27 tumor microenvironment approach.
• Compugen: Israel-based clinical-stage immuno-oncology company developing computational-discovered antibody therapeutics targeting novel immune checkpoints, including PVRIG and TIGIT. Compugen's AI-driven antibody discovery and focus on next-generation immune checkpoints parallels Coherus's portfolio approach to overcoming immune resistance.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/coherus_bio
• Facebookfacebook.com/1657477804520001
• LinkedInlinkedin.com/company/2583026

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries2 records

Funding overview

Funding rounds20 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coherus Biosciences